Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 May;91(5):543–550. doi: 10.1111/j.1349-7006.2000.tb00979.x

Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines

Yoshimi Aoyagi 1, Takashi Kobunai 1, Teruhiro Utsugi 1, Konstanty Wierzba 1, Yuji Yamada ✉
PMCID: PMC5926383  PMID: 10835500

Abstract

6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinol in‐7‐one dihydrochloride (TAS‐103) is a novel anticancer agent that was developed to target both topoisomerase (Topo) I and Topo II. To elucidate its mechanism of action, we have established and characterized TAS‐103‐resistant cells, derived from mouse leukemia (P388), human colon cancer (DLD‐1), and human lung adenocarcinoma (A549) cell lines, by exposure to stepwisely increasing concentrations of TAS‐103 in the culture medium. P388/TAS cells showed only cross‐resistance to VP‐16 and adriamycin (ADR). The Topo II activity in these cells was decreased to below one‐fourth of that in the parental cells, while the Topo I activity remained unchanged. DLD/TAS cells appeared to be cross‐resistant to VP‐16, ADR, camptothecin (CPT), SN‐38 and vincristine (VCR). The enzymatic activities of both Topo I and Topo II in these cells were decreased to one‐fourth of that observed in the parental cells. Furthermore, the decreased activities were accompanied by lower expression at the mRNA and protein levels. A549/TAS cells acquired cross‐resistance to VP‐16, ADR and VCR, though the Topo activities were virtually unchanged. In this cell line, the intracellular accumulation of TAS‐103 was significantly decreased and the expression of multidrug resistance associated protein (MRP) was elevated when compared with the parental cells. The results indicate that the affected activities of Topo I and/or Topo II, and in some instances decreased accumulation of TAS‐103, are associated with the development of resistance to TAS‐103, although the main mechanism of resistance to TAS‐103 varied among cell lines.

Keywords: TAS‐103, Topoisomerases, Resistance

Full Text

The Full Text of this article is available as a PDF (166.9 KB).

REFERENCES

  • 1. ) Chen , A.Y. and Liu , L. F.DNA topoisomerases: essential enzymes and lethal targets . Annu. Rev. Pharmacol. Toxicol. , 34 , 191 – 218 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Takano , H. , Kohno , K. , Matsuo , K. , Matsuda , T. and Kuwano , M.DNA topoisomerase‐targeting antitumor agent and drug resistance . Anticancer Drugs , 3 , 323 – 330 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Utsugi , T. , Aoyagi , K. , Asao , T. , Okazaki , S. , Aoyagi , Y. , Sano , M. , Wierzba , K. and Yamada , Y.Antitumor activity of a novel quinoline derivative, TAS‐103, with inhibitory effects on topoisomerases I and II . Jpn. J. Cancer Res. , 88 , 992 – 1002 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. ) Aoyagi , Y. , Kobunai , T. , Utsugi , T. , Oh‐hara , T. and Yamada , Y.In vitro antitumor activity of TAS‐103, a novel quinoline derivative that targets topoisomerases I and II . Jpn. J. Cancer Res. , 90 , 578 – 588 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Isoe , T. and Tsuruo , T.Decreased expression of DNA topoisomerase I in camptothecin‐resistant tumor cell lines as determined by a monoclonal antibody . Cancer Res. , 50 , 6925 – 6930 ( 1990. ). [PubMed] [Google Scholar]
  • 6. ) Matsuo , K. , Kohno , K. , Takano , H. , Sato , S. , Kiue , A. and Kuwano , M.Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide‐resistant human cancer KB cell lines . Cancer Res. , 50 , 5919 – 5924 ( 1990. ). [PubMed] [Google Scholar]
  • 7. ) Long , B. H. , Wang , L. , Lorico , A. , Wang , R. C. C. , Brattain , M. G. and Casazza , A. M.Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines . Cancer Res. , 51 , 5725 – 5284 ( 1991. ). [PubMed] [Google Scholar]
  • 8. ) Kubota , N. , Nishio , K. , Takeda , Y. , Ohmori , T. , Funayama , Y. , Ogasawara , H. , Ohira , T. , Kunikake , H. , Terashima , Y. and Saijo , N.Characterization of an etoposide‐resistant human ovarian cancer cell line . Cancer Chemother. Pharmacol. , 34 , 183 – 190 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Tamura , H. , Kohchi , C. , Yamada , R. , Ikeda , T. , Koiwai , O. , Patterson , E. , Keene , D. J. , Okada , K. , Kjeidsen , E. , Nishikawa , K. and Andho , T.Molecular cloning of a cDNA of a camptothecin‐resistant human DNA topoisomerase I and identification of mutation sites . Nucleic Acids Res. , 19 , 69 – 75 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Kubota , N. , Kanzawa , F. , Nishio , K. , Takeda , Y. , Ohmori , T. , Fujiwara , Y. , Terashima , Y. and Saijo , N.Detection of topoisomerase I gene point mutation in CPT‐11 resistant lung cancer cell line . Biochem. Biophys. Res. Commun. , 188 , 571 – 577 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Bugg , B. Y. , Danks , M. K. , Beck , W. T. and Suttle , D. P.Expression of a mutant DNA topoisomerase II in CCRFCEM human leukemia cells selected for resistance to teniposide . Proc. Natl. Acad. Sci. USA , 88 , 7654 – 7658 ( 1991. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Saleem , A. , Ibrahin , N. , Patel , M. , Li , X. , Gupta , E. , Mendoza , J. , Pantazis , P. and Rubin , H. E.Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning . Cancer Res. , 57 , 5100 – 5106 ( 1997. ). [PubMed] [Google Scholar]
  • 13. ) Minato , K. , Kanazawa , F. , Nishio , K. , Nakagawa , K. , Fujiwara , Y. and Saijo , N.Characterization of an etoposide‐resistant human small‐cell lung cancer cell line . Cancer Chemother. Pharmacol. , 26 , 313 – 317 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Schneider , E. , Horton , J. K. , Yang , C. H. , Nakagawa , M. and Cowan , K. H.Multidrug resistance‐associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide . Cancer Res. , 54 , 152 – 158 ( 1994. ). [PubMed] [Google Scholar]
  • 15. ) Lautier , D. , Canitrot , Y. , Deeley , R. G. and Cole , S. P. C.Multidrug resistance mediated by the multidrug resistance protein (MRP) gene . Biochem. Pharmacol. , 52 , 967 – 977 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Alley , M. C. , Scudiero , D. A. , Monks , A. , Hursey , M. L. , Czwrwinsky , M. J. , Fine , D. L. , Mayo , J. G. , Shoemaker , R. H. and Boyd , M. R.Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay . Cancer Res. , 48 , 589 – 601 ( 1988. ). [PubMed] [Google Scholar]
  • 17. ) Deffie , A. M. , Batra , J. K. and Goldenberg , G. J.Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin‐sensitive and ‐resistant P388 leukemia cell lines . Cancer Res. , 49 , 58 – 62 ( 1989. ). [PubMed] [Google Scholar]
  • 18. ) Utsugi , T. , Mattern , M. R. , Mirabelli , C. K. and Hanna , N.Potentiation of topoisomerase inhibitor‐induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation . Cancer Res. , 50 , 2636 – 2640 ( 1990. ). [PubMed] [Google Scholar]
  • 19. ) Utsugi , T. , Shibata , J. , Sugimoto , Y. , Aoyagi , K. , Wierzba , K. , Kobunai , T. , Terada , T. , Oh‐hara , T. , Tsuruo , T. and Yamada , Y.Antitumor activity of a novel podophyllotoxin derivative (TOP‐53) against lung cancer and lung metastatic cancer . Cancer Res. , 56 , 2809 – 2814 ( 1996. ). [PubMed] [Google Scholar]
  • 20. ) Desjardin , E. L. , Chen , Y. , Perkins , D. M. , Teixeira , L. , Cave , D. M. and Eisenach , D. K.Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis . J. Clin. Microbiol. , 36 , 1964 – 1968 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. ) Luthra , R. , McBride , J. A. , Cabanillas , F. and Sarris , A.Novel 5′‐exonuclease‐based real‐time PCR assay for detection of t(14;18)(q32;q21) in patients with follicular lymphoma . Am. J. Pathol. , 153 , 63 – 68 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. ) van der Valk , P. , van der Kalken , C. K. , Ketelaas , H. , Boxterman , H. J. , Scheffer , G. L. , Kuiper , C. M. , Tsuruo , T. , Lankerma , C. J. L. M. , Pinedo , H. M. and Scheper , R. J.Distribution of multidrug resistance‐associated P‐glucoprotein in normal and neoplastic human tissue . Ann. Oncol. , 1 , 56 – 64 ( 1990. ). [PubMed] [Google Scholar]
  • 23. ) Scheper , R. J. , Broxterman , H. J. , Scheffer , G. L. , Kaaijk , P. , Dalton , W. S. , van Heijningen , T. H. M. , van Kalken , C. K. , Slovak , M. L. , de Vries , E. G. E. , van der Valk , P. , Meijer , C. J. L. M. and Pinedo , H. M.Overexpression of a Mr 110,000 vesicular protein in non‐P‐glycoprotein‐mediated multidrug resistance . Cancer Res. , 53 , 1475 – 1479 ( 1993. ). [PubMed] [Google Scholar]
  • 24. ) Yabuki , N. , Sasano , H. , Kato , T. , Ohara , S. , Toyota , M. , Nagura , H. , Miyaike , A. , Nozaki , N. and Kikuchi , A.Immunohistochemical study of DNA topoisomerase II in human gastric disorder . Am. J. Pathol. , 149 , 997 – 1007 ( 1996. ). [PMC free article] [PubMed] [Google Scholar]
  • 25. ) Withoff , S. , Vries , E. G. E. , Keith , W. N. , Nienhuis , E. F. , Greef , W. T. A. , Uges , D. R. A. and Mulder , N. H.Differential expression of DNA topoisomerase II α and ‐β on Pgp and MRP‐negative VM26, mAMSA and mitoxantrone resistant sublines of the human SCLC cell line GCL4 . Br. J. Cancer , 74 , 1869 – 1876 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. ) Hazlehurst , L. A. , Foley , N. E. , Gleason‐Guzman , M. C. , Hacker , M. P. , Cress , A. E. , Greenberger , L. W. , De Jong , W. C. and Dalton , W. S.Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line . Cancer Res. , 59 , 1021 – 1028 ( 1999. ). [PubMed] [Google Scholar]
  • 27. ) Deruddre , S. , Dalaporte , C. and Jacquemin‐Sablom , A.Role of topoisomerase II β in the resistance of 9‐OH‐ellipticine‐resistant Chinese hamster fibroblast to topoisomerase II inhibitors . Cancer Res. , 57 , 4301 – 4308 ( 1997. ). [PubMed] [Google Scholar]
  • 28. ) Austin , C. A. and Marsh , K. L.Eukaryotic DNA topoisomerase IIβ BioEssays , 20 , 215 – 226 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Woessner , R. D. , Mattern , M. R. , Mirabelli , C. K. , Johnson , R. K. and Drake , F. H.Proliferation‐ and cell cycle‐dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH‐3T3 cells . Cell Growth Differ. , 2 , 209 – 214 ( 1991. ). [PubMed] [Google Scholar]
  • 30. ) Prosperi , E. , Marchese , G. and Astaldi‐Ricotti , G. C. B.Expression of the 170‐kDa and 180‐kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes . Cell prolif. , 27 , 257 – 267 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Turnbull , R. M. , Meczes , E. L. , Perenna Rogers , M. , Lock , R. B. , Sullivan , D. M. , Finlay , G. J. , Bagulay , B. C. and Austin , C. A.Carbamate analogues of amsacrine active against non‐cycling cells: relative activity against topoisomerase II α and β . Cancer Chemother. Pharmacol. , 44 , 275 – 282 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Baguley , B. C. , Leteurtre , F. , Riou , J. F. , Finlay , G. J. and Pommier , Y.A carbamate analogue of amsacrine with activity against non‐cyclin cells stimulates topoisomerase II cleavage at DNA sites distinct from amsacrine . Eur. J. Cancer , 33 , 272 – 279 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Tronov , V. A. , Konoplyannikov , M. A. , Nikolskaya , T. A. and Konstantinov , E. A.Apoptosis of unstimulated human lymphocyte and DNA strand breaks induced by the topoisomerase Ii inhibitor etoposide (VP‐16) . Biochemistry , 64 , 345 – 352 ( 1999. ). [PubMed] [Google Scholar]
  • 34. ) Young , L. C. , Campling , B. G. , Voskoglou‐Nomikos , T. , Cole , S. P. C. , Deeley , R. G. and Gerlach , J. H.Expression of multidrug resistance protein‐related genes in lung cancer: correlation with drug response . Clin. Cancer Res. , 5 , 673 – 680 ( 1999. ). [PubMed] [Google Scholar]
  • 35. ) Lorico , A. , Rappa , G. , Finchi , A. R. , Yang , D. , Flavell , A. R. and Sartorelli , C. A.Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP‐16) and increased levels of glutathione . Cancer Res. , 57 , 5238 – 5242 ( 1997. ). [PubMed] [Google Scholar]
  • 36. ) Rappa , G. , Lorico , A. , Flavell , A. R. and Sartorelli , C. A.Evidence that the multidrug resistance protein (MRP) functions as a co‐transporter of glutathione and natural product toxins . Cancer Res. , 57 , 5232 – 5237 ( 1997. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES